Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Poll






Jul 29, 2011

Gene Patenting Case Against Myriad Genetics

Today, the Court of Appeals for the Federal Circuit affirmed in part and reversed in part the original decision in Association for Molecular Pathology, et al. v. United States Patent and Trademark Office, et al. Specifically, it stated that Myriad Genetics' composition claims to isolated DNA were valid. What's your thoughts on this latest decision in the long-standing debate over patenting genes.

Do you agree with the Court's most recent decision validating Myriad's composition claims to isolated DNA?

Yes
 
  25.5%
No
 
  62.7%
Undecided
 
  11.8%



Related content